Evidence map›Paper›PMID 28401900›Full record

ArticleEuropean journal of human genetics : EJHG2017

An efficient and flexible test for rare variant effects.

Shonosuke Sugasawa, Hisashi Noma, Takahiro Otani, Jo Nishino, Shigeyuki Matsui

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shonosuke SugasawaRisk Analysis Research Center, The Institute of Statistical Mathematics, Tokyo, Japan.
Hisashi NomaDepartment of Data Science, The Institute of Statistical Mathematics, Tokyo, Japan.
Takahiro OtaniRisk Analysis Research Center, The Institute of Statistical Mathematics, Tokyo, Japan.
Jo NishinoCore Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan.
Shigeyuki MatsuiCore Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Tokyo, Japan.

Funding

UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
NCATS NIH HHS UL1 TR001105
6 · The paper itself

Abstract

Since it has been claimed that rare variants with extremely small allele frequency play a crucial role in complex traits, there is great demand for the development of a powerful test for detecting these variants. However, due to the extremely low frequencies of rare variants, common statistical testing methods do not work well, which has motivated recent extensive research on developing an efficient testing procedure for rare variant effects. Many studies have suggested effective testing procedures with reasonably high power under some presumed assumptions of parametric statistical models. However, if the parametric assumptions are violated, these tests are possibly under-powered. In this paper, we develop an optimal, powerful statistical test called the aggregated conditional score test (ACST) for simultaneously testing M rare variant effects without restrictive parametric assumptions. The proposed test uses a test statistic aggregating the conditional score statistics of effect sizes of M rare variants. In simulation studies, ACST generally performed well compared with the two most commonly used tests, the optimal sequence kernel association test (SKAT-O) and Kullback-Leibler distance test. Finally, we demonstrate the performance and practical utility of ACST using the Dallas Heart Study data.

Indexed as

AlgorithmsGene FrequencyGenome-Wide Association StudyHumansModels, GeneticMutation

Identifiers

PMID28401900
PMCPMC5477370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.